Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
A Registry of Tuberculosis Cases in the CPCRA
NCT00000785 · View on ClinicalTrials.gov ↗
Study Summary
PRIMARY: To estimate the proportion of tuberculosis patients in the CPCRA who have drug-resistant tuberculosis (TB) and to describe the patterns of drug resistance. SECONDARY: To compare drug resistance data on the Mycobacterium tuberculosis isolates of HIV-infected patients to those of HIV-uninfected patients who are being followed in the CPCRA. To assess the relationship of resistance data with geographic, demographic, and HIV and TB risk factor information. Geographic areas and demographic subgroups affected by the TB epidemic appear to be congruent and associated with the concurrent HIV epidemic. The total number of CPCRA patients who will develop, or who have experienced, confirmed TB is unknown. It is critical to determine the depth and breadth of the current problem of drug-resistant TB.
Conditions Studied
Study Locations (13)
New York
- Addiction Research and Treatment Corp — Brooklyn
- Clinical Directors Network of Region II — New York
- Harlem AIDS Treatment Group / Harlem Hosp Ctr — New York
- Bronx Lebanon Hosp Ctr — The Bronx
Michigan
- Comprehensive AIDS Alliance of Detroit — Detroit
- Henry Ford Hosp — Detroit
Colorado
- Denver CPCRA / Denver Public Hlth — Denver
District of Columbia
- Veterans Administration Med Ctr / Regional AIDS Program — Washington D.C.
Illinois
- AIDS Research Alliance - Chicago — Chicago
Louisiana
- Louisiana Comm AIDS Rsch Prog / Tulane Univ Med — New Orleans
New Jersey
- North Jersey Community Research Initiative — Newark
Oregon
- Portland Veterans Adm Med Ctr / Rsch & Education Grp — Portland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,509 participants |
| Start Date | 1992-08 |
| Est. Completion | 1994-06 |
Interested in This Trial?
Always speak with your doctor before enrolling in a clinical trial.
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00000785
The ClinicalTrials.gov registry entry for NCT00000785 describes a study currently listed as completed. It is categorized as an unspecified phase, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 1,509 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Institute of Allergy and Infectious Diseases (NIAID), which has 1,295 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.
The record links to 2 conditions, with HIV Infections appearing as the primary indexed condition, and to 0 interventions. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.
Geographic footprint matters for practical reasons: NCT00000785 reports 13 study locations spanning 9 distinct geographic areas — top geographies include New York, Michigan, Colorado. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.
Frequently Asked Questions
What is clinical trial NCT00000785 about?
NCT00000785 is a clinical study titled "A Registry of Tuberculosis Cases in the CPCRA". PRIMARY: To estimate the proportion of tuberculosis patients in the CPCRA who have drug-resistant tuberculosis (TB) and to describe the patterns of drug resistance. SECONDARY: To compare drug resistance data on the Mycobacterium tuberculosis isolates of HIV-infected patients to those of HIV-uninfec...
What is the current status of trial NCT00000785?
This trial is currently completed. The enrollment target is 1,509 participants. The study started on 1992-08. Estimated completion is 1994-06.
What conditions does trial NCT00000785 study?
This clinical trial studies the following conditions: HIV Infections, Tuberculosis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.
Who is sponsoring clinical trial NCT00000785?
This trial is sponsored by National Institute of Allergy and Infectious Diseases (NIAID), which has 1,295 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.
Where is trial NCT00000785 being conducted?
This trial has 13 study locations across Colorado, District of Columbia, Illinois, Louisiana, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How Clinical Trials Work
Understand phases 1-4, trial design, randomization, and the informed consent process.
Patient Rights in Clinical Trials
Your rights as a participant: consent, withdrawal, privacy, and who to contact.
Finding the Right Clinical Trial
A practical guide to searching trials, understanding eligibility, and evaluating options.
All Guides
Browse our complete library of clinical trial educational resources.
Read our methodology — how this data is sourced, computed, and verified.